



US008785415B2

(12) **United States Patent**
Bodor et al.

(10) **Patent No.:** **US 8,785,415 B2**
(45) **Date of Patent:** ***Jul. 22, 2014**

(54) **ORAL FORMULATIONS OF CLADRIBINE**

FOREIGN PATENT DOCUMENTS

- (75) Inventors: **Nicholas S. Bodor**, Bal Harbour, FL (US); **Yogesh Dandiker**, Toronto (CA)
- (73) Assignee: **Ares Trading S.A.**, Aubonne (CH)
- (*) Notice: Subject to any disclaimer, the term of this patent is extended or adjusted under 35 U.S.C. 154(b) by 357 days.

This patent is subject to a terminal disclaimer.

DE	31 18 218 A1	4/1982	
DE	33 17 064 A1	11/1984	
EP	0 094 157 A1	11/1983	
EP	0 149 197 B1	7/1985	
EP	0 197 571 A2	10/1986	
GB	2 189 245 A	10/1987	
WO	WO 90/12035 A1	10/1990	
WO	WO 9718839 A1 *	5/1997 A61K 47/48
WO	98/55148 A1	12/1998	
WO	WO 99/42111	8/1999	
WO	99/62958 A1	12/1999	

(21) Appl. No.: **12/986,310**

(22) Filed: **Jan. 7, 2011**

(65) **Prior Publication Data**
US 2011/0097306 A1 Apr. 28, 2011

Related U.S. Application Data

- (63) Continuation of application No. 10/551,205, filed as application No. PCT/US2004/009387 on Mar. 26, 2004, now Pat. No. 7,888,328.
- (60) Provisional application No. 60/458,922, filed on Mar. 28, 2003, provisional application No. 61/484,756, filed on Jul. 2, 2003, provisional application No. 60/541,247, filed on Feb. 4, 2004.

(51) **Int. Cl.**
A61K 31/7076 (2006.01)
A61K 47/40 (2006.01)

(52) **U.S. Cl.**
USPC **514/46**; 514/58

(58) **Field of Classification Search**
CPC A61K 31/7076; A61K 47/40; A61K 47/48969
USPC 514/46, 58
See application file for complete search history.

(56) **References Cited**

U.S. PATENT DOCUMENTS

3,459,731 A	8/1969	Gramera et al.
4,383,992 A	5/1983	Lipari
4,478,995 A	10/1984	Shinoda et al.
4,497,803 A	2/1985	Harada et al.
4,535,152 A	8/1985	Szejtli et al.
4,596,795 A	6/1986	Pitha
4,659,696 A	4/1987	Hirai et al.
4,727,064 A	2/1988	Pitha
4,764,604 A	8/1988	Müller
4,870,060 A	9/1989	Müller
5,106,837 A	4/1992	Carson et al.
5,310,732 A	5/1994	Carson et al.
5,401,724 A	3/1995	Beutler
5,424,296 A	6/1995	Saven et al.
5,506,214 A	4/1996	Beutler
5,510,336 A	4/1996	Saven et al.
6,174,873 B1	1/2001	Wrenn, Jr. et al.
6,194,395 B1	2/2001	Schultz et al.
6,239,118 B1	5/2001	Schatz et al.
6,407,079 B1	6/2002	Müller et al.

OTHER PUBLICATIONS

Redenti et al., *Int. J. Pharm.*, 1996, 129, p. 289-294.*
Pitha et al., *Life Sci.*, 1998, 43, p. 493-502.*
Drugs in Japan (Nihon Iyakuhinn Shu), 2004 edition, Jihou Inc. Mar. 1, 2003, pp. 651-654, "Cladribine" (especially, "Composition")—relevance explained in Jan. 10, 2012, Japanese Official Action. Official Action issued on Jan. 10, 2012, in corresponding Japanese Patent Application No. 2006-509371, and an English language translation of the Official Action.
Tarasiuk et al., "Stability of 2-Chloro-2'-Deoxyadenosine at Various pH and Temperature", *Archivum Immunologiae et Therapiae Experimentalis*, vol. 42, pp. 13-15, 1994, published by Birkhauser Publishers Ltd., Basel, Switzerland.
Romine et al., "A Double-Blind, Placebo-Controlled, Randomized Trial of Cladribine in Relapsing-Remitting Multiple Sclerosis", *Proceedings of the Association of American Physicians*, vol. 111, No. 1, pp. 35-44, 1999, published by Blackwell Publishing, Malden, MA.
Tortorella et al., *Current Opinion on Investigational Drugs*, 2(12), pp. 1751-1756, 2001, published by PharmaPress Ltd., London, GB.
Selby et al., "Safety and Tolerability of Subcutaneous Cladribine Therapy in Progressive Multiple Sclerosis", *Can. J. Neurol Sci.*, vol. 25, pp. 295-299, 1998, published by Canadian Journal of Neurological Science, Calgary, Canada.
Rice et al., "Cladribine and progressive MS Clinical and MRI outcomes of a multicenter controlled trial", *Neurology*, vol. 54, pp. 1145-1155, 2000, published by Lippincott Williams and Wilkins, Hagerstown, MD.
Liliemark et al., "On the Bioavailability of Oral and Subcutaneous 2-Chloro-2'-Deoxyadenosine in Humans: Alternative Routes of Administration", *Journal of Clinical Oncology*, vol. 10, No. 10, pp. 1514-1518, 1992, published by American Society of Clinical Oncology, Alexandria, VA.
Karlsson et al., "Oral cladribine for B-cell chronic lymphocytic leukaemia: report of a phase II trial with a 3-d, 3-weekly schedule in untreated and pretreated patients, and a long-term follow-up of 126 previously untreated patients", *British Journal of Haematology*, vol. 116, pp. 538-548, 2002, published by Blackwell Science Ltd., Oxford, UK.

(Continued)

Primary Examiner — Shaojia Anna Jiang
Assistant Examiner — Jonathan S Lau
(74) *Attorney, Agent, or Firm* — Dentons US LLP

(57) **ABSTRACT**

Provided are compositions of cladribine and cyclodextrin which are especially suited for the oral administration of cladribine.


(56)

References Cited

OTHER PUBLICATIONS

- Liliemark, "The Clinical Pharmacokinetics of Cladribine" *Clin. Pharmacokinet.*, vol. 32 (2), pp. 120-131, 1997, published by Adis International Limited, Wolters Kluwer Health, Yardley, PA.
- Nakai et al., "Effects of Grinding on the Physical and Chemical Properties of Crystalline Medicinals with Microcrystalline Cellulose V: Comparison with Tri-O-methyl- β -cyclodextrin Ground Mixtures", *Chem. Pharm. Bulletin*, vol. 28(5), pp. 1552-1558, 1980, published by Pharmaceutical Society of Japan, Tokyo, Japan.
- Saenger, "Cyclodextrin Inclusion Compounds in Research and Industry", *Angew. Chem. Int. Ed. Engl.*, vol. 19, pp. 344-362, 1980, published by Verlag Chemie, GmbH, Weinheim, Germany.
- Tang et al., "Design of Freeze-Drying Processes for Pharmaceuticals: Practical Advice", *Pharmaceutical Research*, vol. 21, No. 2, pp. 191-200, 2004, Springer, The Netherlands.
- Gao, Shen, *New Dosage Form and New Technology of Modern Drugs*, first edition, Jan. 2002, Chapter 6, Section 3 (III) Procedures, p. 105, lines 25-29 (published by People's Military Medical Publisher) and English translation thereof.
- Albertioni et al., "On the bioavailability of 2-chloro-2'-deoxyadenosine (CdA)", *Eur J Clin Pharmacol.*, vol. 44, pp. 579-582, 1993, Springer-Verlag, Germany.
- Ahn et al., "Chiral Recognition in Gas-Phase Cyclodextrin: Amino Acid Complexes—Is the Three Point Interaction Still Valid in the Gas Phase?", *J Am Soc Mass Spectrom.*, vol. 12, pp. 278-287, 2001, Elsevier Science, Inc., US.
- Bakthiar et al., "A study of the complexation between dimethyl- β -cyclodextrin and steroid hormones using electrospray ionization mass spectrometry", *Rapid Communications in Mass Spectrometry*, vol. 11, pp. 1478-1481, 1997, John Wiley and Sons Ltd, England.
- Beutler et al., "The treatment of chronic progressive multiple sclerosis with cladribine", *Proc. Natl. Acad. Sci. USA, Medical Sciences*, vol. 93, pp. 1716-1720, 1996, National Academy of Sciences, US.
- Cheng et al., "Measurement of chiral complexes of cyclodextrin and amino acids by electrospray ionization time-of-flight mass spectrometry", *J. Mass Spectrom.*, vol. 36, pp. 834-836, 2001, John Wiley & Sons, Ltd., England.
- Choi et al., "FT-Raman and FT-IR Spectra of the Non-steroidal Anti-inflammatory Drug Ketoprofen Included in Cyclodextrins", *Analytical Sciences*, vol. 17 Supplement, pp. i785-i788, 2001, The Japan Society for Analytical Chemistry, Japan.
- Giordano et al., "Thermal analysis of cyclodextrins and their inclusion compounds", *Thermochimica Acta* 380, pp. 123-151, 2001, Elsevier Science B.V., The Netherlands.
- Hwang et al., "Water Suppression That Works. Excitation Sculpting Using Arbitrary Waveforms and Pulsed Field Gradients", *Journal of Magnetic Resonance*, Series A, vol. 112, pp. 275-279, 1995, Academic Press, Inc., US.
- Lamcharfi et al., "Electrospray Ionization Mass Spectrometry in Supramolecular Chemistry: Characterization of Non-covalent Cyclodextrin Complexes", *Journal of Mass Spectrometry*, vol. 31, pp. 982-986, 1996, John Wiley & Sons, Ltd., England.
- Lofsson et al., "Pharmaceutical Applications of Cyclodextrin. 1. Drug Solubilization and Stabilization", *Journal of Pharmaceutical Sciences*, vol. 85, No. 10, pp. 1017-1025, 1996, American Pharmaceutical Association and the American Chemical Society, US.
- Meier et al., "The Influence of β - and γ -Cyclodextrin Cavity Size on the Association Constant with Decanoate and Octanoate Anions", *Journal of Inclusion Phenomena and Macrocyclic Chemistry*, vol. 40, pp. 291-295, 2001, Kluwer Academic Publishers, The Netherlands.
- Mura et al., "Interactions of ketoprofen and ibuprofen with β -cyclodextrins in solution and in the solid state", *International Journal of Pharmaceutics*, vol. 166, pp. 189-203, 1998, Elsevier Science B.V., The Netherlands.
- Nolan et al., "Preparation of Vesicles and Nanoparticles of Amphiphilic Cyclodextrins Containing Labile Disulfide Bonds", *Langmuir*, vol. 19, pp. 4469-4472, 2003, American Chemical Society, US.
- Ramanathan et al., "Electrospray Ionization Mass Spectrometric Study of Encapsulation of Amino Acids by Cyclodextrins", *J. Am Soc Mass Spectrom.*, vol. 6, pp. 866-871, 1995, American Society for Mass Spectrometry, US.
- Redenti et al., "Raman and Solid State ^{13}C -NMR Investigation of the Structure of the 1 : 1 Amorphous Piroxicam : β -Cyclodextrin Inclusion Compound", *Biospectroscopy*, vol. 5, pp. 243-251, 1999, John Wiley & Sons, Inc., US.
- Sipe et al., "Cladribine in treatment of chronic progressive multiple sclerosis", *The Lancet*, vol. 344, pp. 9-13, 1994, Lancet Publishing Group, England.
- Szejtli, "Introduction and General Overview of Cyclodextrin Chemistry", *Chem. Rev.*, vol. 98, pp. 1743-1753, 1998, American Chemical Society, US.
- Uekama et al., "Cyclodextrin Drug Carrier Systems", *Chem. Rev.*, vol. 98, pp. 2045-2076, 1998, American Chemical Society, US.
- Uekama et al., "Peracylated β -Cyclodextrins as Novel Sustained-release Carriers for a Water-soluble Drug, Molsidomine", *J. Pharm. Pharmacol.*, vol. 46, pp. 714-717, 1994, Pharmaceutical Press, England.
- Taddei et al., "Influence of Environment on Piroxicam Polymorphism: Vibrational Spectroscopic Study", *Biopolymers (Biospectroscopy)*, vol. 62, pp. 68-78, 2001, John Wiley & Sons, Inc., US.
- Van Axel Castelli et al. "Characterisation of an Inclusion Complex Between Cladribine and 2-Hydroxypropyl- β -Cyclodextrin." *J. Pharm.Sci.*, vol. 97, No. 9, Sep. 2008, pp. 3897-3906, Wiley InterScience and the American Pharmacists Association, US.
- Drugs.com, "Oral Investigational Treatment Cladribine Tablets for Multiple Sclerosis Significantly Reduced Relapse Rate in Phase III Pivotal Trial," accessed online Feb. 3, 2009, at http://www.drugs.com/clinical_trials/oral-investigational-cladribine-multiple-sclerosis.
- "Sero's Oral Cladribine for the Treatment of Multiple Sclerosis Awarded Fast Track Status by FDA", accessed online Feb. 3, 2009 at <http://prnewswire.com>.
- Merck Sero News Release, "Two-year Phase III Data Presented at AAN 61st Annual Meeting Show Positive Outcome of Cladribine Tablets in Patients with Multiple Sclerosis", Apr. 29/30, 2009, available online.
- Lofsson et al., "Self-Association and Cyclodextrin Solubilization of Drugs", *Journal of Pharmaceutical Sciences*, 2002, 91(11), p. 2307-2316.
- Entry for Liquid, Britannica Online Encyclopedia, <http://www.search.eb.com/>, accessed online Dec. 31, 2008.
- Suzuki, et al., "Application of Freezing Point Depression to Drug Interaction Studies," *Chem. Pharm. Bull.*, 1988 36(2), p. 720-725.
- Suzuki et al., "A Study of 1:1 Plus 1:2 Complexes Between Barbiturate and α -Cyclodextrin Using the Freezing Point Depression Method," *Chem. Pharm. Bull.*, 1993, 41(8), p. 1444-1447.
- International Search Report dated Oct. 12, 2004 for PCT/US2004/009387, filed Mar. 26, 2004.
- PCT International Preliminary Report on Patentability and Written Opinion for International Application No. PCT/US2004/009387, International Filing date Mar. 26, 2004.

* cited by examiner



1


ORAL FORMULATIONS OF CLADRIBINE

CROSS-REFERENCE TO EARLIER APPLICATIONS

This application is a continuation of prior U.S. application Ser. No. 10/551,205 filed Nov. 14, 2006, now U.S. Pat. No. 7,888,328, which is the US national stage of International Application No. PCT/US2004/009387, filed Mar. 26, 2004, which claims benefit under 35 U.S.C. §119(e) of U.S. Provisional Application No. 60/458,922, filed Mar. 28, 2003; of U.S. Provisional Application No. 60/484,756, filed Jul. 2, 2003; and of U.S. Provisional Application No. 60/541,247, filed Feb. 4, 2004, all of said applications being hereby incorporated by reference herein in their entireties and relied upon.

BACKGROUND OF THE INVENTION

Cladribine, which is an acid-labile drug, has the chemical structure as set forth below:



It is also known as 2-chloro-2'-deoxyadenosine or 2-CdA. Cladribine exists as a white, nonhygroscopic, crystalline powder, consisting of individual crystals and of crystalline aggregates.

Cladribine is an antimetabolite which has use in the treatment of lymphoproliferative disorders. It has been used to treat experimental leukemias such as L1210 and clinically for hairy cell leukemia and chronic lymphocytic leukemia as well as Waldenstrom's macroglobulinaemia. It has also been used as an immunosuppressive agent and as a modality for the treatment of a variety of autoimmune conditions including rheumatoid arthritis, inflammatory bowel disease (e.g., Crohn's disease, ulcerative colitis) and multiple sclerosis (see e.g., J. Liliemark, *Clin. Pharmacokinet.*, 32(2): 120-131, 1997). It has also been investigated, either experimentally or clinically in, for example, lymphomas, Langerhan's cell histiocytosis, lupus erythematosus, chronic plaque psoriasis, Sezary syndrome, Bing-Neel syndrome, recurrent glioma, and solid tumors.

Oral delivery of drugs is often preferred to parenteral delivery for a variety of reasons, foremost patient compliance, or for cost or therapeutic considerations. Patient compliance is enhanced insofar as oral dosage forms alleviate repeated health care provider visits, or the discomfort of injections or prolonged infusion times associated with some active drugs. At a time of escalating health care costs, the reduced costs associated with oral administration versus parenteral administration costs gain importance. The cost of parenteral administration is much higher due to the requirement that a health care professional administer the cladribine in the health care

2

instances, therapeutic considerations such as the need for a slow release of cladribine over a prolonged period of time may be practically met only by oral or transmucosal delivery.

However, to date the oral delivery of cladribine has been plagued by low bioavailability (see, e.g., J. Liliemark et al., *J. Clin. Oncol.*, 10(10): 1514-1518, 1992), and suboptimal interpatient variation (see, e.g., J. Liliemark, *Clin. Pharmacokinet.*, 32 (2): 120-131, 1997). See also, A. Tarasuik, et al. reporting poor absorption and pH dependent lability (*Arch. Immunol. et Therapiae Exper.*, 42: 13-15, 1994).

Cyclodextrins are cyclic oligosaccharides composed of cyclic α -(1 \rightarrow 4) linked D-glucopyranose units. Cyclodextrins with six to eight units have been named α -, β - and γ -cyclodextrin, respectively. The number of units determines the size of the cone-shaped cavity which characterizes cyclodextrins and into which drugs may be included to form stable complexes. A number of derivatives of α -, β - and γ -cyclodextrin are known in which one or more hydroxyl groups is/are replaced with ether groups or other radicals. These compounds are thus known complexing agents and have been previously used in the pharmaceutical field to form inclusion complexes with water-insoluble drugs and to thus solubilize them in aqueous media.

Recently, Schultz et al., in U.S. Pat. No. 6,194,395 B1, have described complexing and solubilizing cladribine with cyclodextrin. The Schultz et al. patent primarily addresses the problems inherent in previously described aqueous formulations of cladribine, particularly for subcutaneous and intramuscular injection. Schultz et al. have found that cladribine is not only significantly more soluble in aqueous media when formulated with cyclodextrin, but also is more stable against acid-catalyzed hydrolysis when combined with cyclodextrin. The latter finding is taught to be of particular benefit in the formulation of solid oral dosage forms, where the compound would normally undergo hydrolysis in the acid pH of the stomach contents. Schultz et al. do not appear to have described any actual work in connection with solid oral dosage forms. In fact, they describe only one method of preparing the solid dosage form, which is a melt extrusion process, in which the cladribine and cyclodextrin are mixed with other optional additives and then heated until melting occurs. Furthermore, the broad dosage ranges of 1 mg to 15 mg of cladribine and 100 mg to 500 mg of cyclodextrin listed in the patent suggest no criticality to the particular amount of cyclodextrin to be present with a given amount of cladribine in a solid oral dosage form. Indeed, these dosage ranges include many combinations which may be suitable as mixtures but not for complex formation. For example, a ratio of 1 mg of cladribine to 500 mg of cyclodextrin contains too much cyclodextrin, so that the drug would not readily leave the complex and achieve its therapeutic function. On the other hand, 15 mg of cladribine and only 100 mg of cyclodextrin would not be enough to complex that amount of cladribine.

The Schultz et al., patent does suggest improving the stability of cladribine in oral dosage forms by combining/complexing it with cyclodextrin, but does not suggest improving the drug's oral bioavailability by such means; in fact, the patent does not describe or suggest a method for enhancing or maximizing the bioavailability of cladribine from a solid oral dosage form of cladribine and cyclodextrin, or a composition specially designed to do so.

Many workers have studied the solubility of specific drugs in water containing various concentrations of selected cyclodextrins in order to demonstrate that increasing concentrations of cyclodextrins increase the solubility of the drugs at

3

been performed by various workers in order to elucidate the nature of the complex formation, for example, whether the cyclodextrin and drug form a 1:1 complex or a 1:2 complex; see, for example, Harada et al. U.S. Pat. No. 4,497,803, relating to inclusion complexes of lankacidin-group antibiotics with cyclodextrin, and Shinoda et al. U.S. Pat. No. 4,478,995, relating to a complex of an acid addition salt of (2'-benzylloxycarbonyl)phenyl trans-4-guanidinomethylcyclohexanecarboxylate with a cyclodextrin.

While Schultz et al. teach that a cladribine-cyclodextrin complex improves the water solubility and acid stability of cladribine, the art does not suggest how to maximize or enhance the benefits of the complexation in terms of bioavailability and interpatient variation when the complex is to be administered in a solid oral dosage form.

SUMMARY OF THE INVENTION

It has now been found that amorphous cyclodextrins can be combined with cladribine to form a particularly advantageous product which can be incorporated into a solid oral dosage form. This product is a complex cladribine-cyclodextrin complex, and the solid oral dosage form containing it improves oral bioavailability and/or achieves lower interpatient and/or intrapatient variation of the drug.

The present invention provides a complex cladribine-cyclodextrin complex which is an intimate amorphous admixture of (a) an amorphous inclusion complex of cladribine with an amorphous cyclodextrin and (b) amorphous free cladribine associated with amorphous cyclodextrin as a non-inclusion complex, and a pharmaceutical composition comprising said complex, formulated into a solid oral dosage form. Thus, the cyclodextrin itself is amorphous, the inclusion complex with cladribine is amorphous (and is preferably saturated with cladribine) and the free cladribine which forms the non-inclusion complex is amorphous.

The invention also provides a method for increasing or enhancing the oral bioavailability of cladribine comprising orally administering to a subject in need thereof, a pharmaceutical composition comprising a complex cladribine-cyclodextrin complex which is an intimate amorphous admixture of (a) an amorphous inclusion complex of cladribine with an amorphous cyclodextrin and (b) amorphous free cladribine associated with amorphous cyclodextrin as a non-inclusion complex, formulated into a solid oral dosage form which maximizes the amount of cladribine in the inclusion and non-inclusion complexes.

The invention further provides for treatment of conditions responsive to administration of cladribine in mammals by administering thereto the composition of the invention. Use of cladribine in the preparation of the pharmaceutical compositions of the invention for administration to treat cladribine-responsive conditions and for enhancing the oral bioavailability of cladribine is also provided.

Still further, the invention provides a process for the preparation of a complex cladribine-cyclodextrin complex which comprises the steps of:

(i) combining cladribine and an amorphous cyclodextrin in water at a temperature of from about 40 to about 80° C. and maintaining said temperature for a period of from about 6 to about 24 hours;

(ii) cooling the resultant aqueous solution to room temperature; and

(iii) lyophilizing the cooled solution to afford an amorphous product; and

(iv) formulating the amorphous product into a solid oral dosage form.

4

In yet a further aspect the invention provides a pharmaceutical composition obtainable by a process comprising the steps of:

(i) combining cladribine and an amorphous cyclodextrin in water at a temperature of from about 40 to about 80° C. and maintaining said temperature for a period of from about 6 to about 24 hours;

(ii) cooling the resultant aqueous solution to room temperature;

(iii) lyophilizing the cooled solution to afford an amorphous product; and

(iv) formulating the amorphous product into a solid oral dosage form.

BRIEF DESCRIPTION OF THE DRAWING

A more complete appreciation of the invention and its many attendant advantages will be readily understood by reference to the following detailed description and the accompanying drawing, wherein the sole FIGURE is a graphical representation of the results of a phase solubility study where various molar concentrations of hydroxypropyl- β -cyclodextrin (HP β CD) are plotted against various cladribine molar concentrations, with (●) representing the data points obtained for complexation under conditions specified in EXAMPLE 2 below.

DETAILED DESCRIPTION OF THE INVENTION

Throughout the instant specification and claims, the following definitions and general statements are applicable.

The patents, published applications, and scientific literature referred to herein establish the knowledge of those with skill in the art and are hereby incorporated by reference in their entirety to the same extent as if each was specifically and individually indicated to be incorporated by reference. Any conflict between any reference cited herein and the specific teachings of this specification shall be resolved in favor of the latter. Likewise, any conflict between an art-understood definition of a word or phrase and a definition of the word or phrase as specifically taught in this specification shall be resolved in favor of the latter.

The term "inclusion complex" as used herein refers to a complex of cladribine with the selected cyclodextrin wherein the hydrophobic portion of the cladribine molecule (the nitrogen-containing ring system) is inserted into the hydrophobic cavity of the cyclodextrin molecule. This is often referred to simply as a cyclodextrin complex of the drug.

The term "non-inclusion complex" refers to a complex which is not an inclusion complex; rather than the hydrophobic portion of cladribine being inserted in the cyclodextrin cavity, the non-inclusion complex is formed primarily by hydrogen-bonding of the hydroxyls and amino group on "free" cladribine, (i.e. cladribine not in the inclusion complex) to the hydroxyls on the exterior of the cyclodextrin torus (e.g. in the case of hydroxypropyl- β -cyclodextrin, hydroxypropyl and hydroxyl groups on the glucose rings). This is a more loosely-held association than an inclusion complex.

As used herein, whether in a transitional phrase or in the body of a claim, the terms "comprise(s)" and "comprising" are to be interpreted as having an open-ended meaning. That is, the terms are to be interpreted synonymously with the phrases "having at least" or "including at least". When used in the context of a process, the term "comprising" means that the process includes at least the recited steps, but may include

Explore Litigation Insights

Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

Real-Time Litigation Alerts



Keep your litigation team up-to-date with **real-time alerts** and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

Advanced Docket Research



With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

Analytics At Your Fingertips



Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

LAW FIRMS

Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

FINANCIAL INSTITUTIONS

Litigation and bankruptcy checks for companies and debtors.

E-DISCOVERY AND LEGAL VENDORS

Sync your system to PACER to automate legal marketing.